预约演示
更新于：2025-05-30
Apatinib Mesylate
甲磺酸阿帕替尼
更新于：2025-05-30
概要
基本信息
在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、孤儿药 (欧盟)、优先审评 (中国)、突破性疗法 (中国)、特殊审批 (中国)、孤儿药 (韩国)、国家科技重大专项 (中国) |
登录后查看时间轴
结构/序列
分子式C25H27N5O4S |
InChIKeyFYJROXRIVQPKRY-UHFFFAOYSA-N |
CAS号1218779-75-9 |
关联
869
项与 甲磺酸阿帕替尼 相关的临床试验NCT06881017
Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping: an Umbrella Phase II Exploratory Clinical Study
NCT06973330
Sintilimab Plus Apatinib and SOX as First-line Treatment in Patients With AFP Gastric or Gastroesophageal Junction Adenocarcinoma: a Single-arm, Multi-center, Phase II Trial
NCT06913777
An Open-Label, Multicenter, Randomized Controlled Phase III Clinical Study of Neoadjuvant Chemotherapy Based on SNF Classification With or Without Precision Medicine Agents for Early-Stage or Locally Advanced HR+/HER2- Breast Cancer
100 项与 甲磺酸阿帕替尼 相关的临床结果
登录后查看更多信息
100 项与 甲磺酸阿帕替尼 相关的转化医学
登录后查看更多信息
100 项与 甲磺酸阿帕替尼 相关的专利（医药）
登录后查看更多信息
2,811
项与 甲磺酸阿帕替尼 相关的文献（医药）2025-12-01Journal of Gastrointestinal Cancer
Third- or Further-Line Treatment in Patients with MSS Type Metastatic Colorectal Cancer
Article
作者: Gou, Miaomiao ; Qian, Niansong ; Dai, Guanghai ; Zhang, Yong ; Wang, Zhikuan
BACKGROUND:
The survival benefit from later-line treatment for patients with metastatic colorectal cancer (mCRC) remains disappointing. Here, in a real-world study, we were aimed to evaluate which choice will affect the survival of mCRC patients after standard treatment in Chinese patients.
METHODS:
A total of 129 patients with refractory mCRC were involved in the study. They received targeted monotherapy or combined with chemo-agents or PD-1 inhibitor before death. Overall survival (OS) and progression-free survival (PFS) were reviewed and evaluated from clinical features and treatment options.
RESULTS:
Among the 129 patients, the median age was 56 years (25-81). The mOS from third-line was 12.5 months. OS of patients who treated with chemo plus targeted therapy group in third-line was shown to be superior to pd-1 inhibitor in combination with antiangiogenic agents or antiangiogenic monotherapy group (15.6 m vs. 10.5 m vs. 8.4 m, p < 0.05). Patients had received triplet-drugs (bevacizumab plus low-dose irinotecan and oxaliplatin) and had prolonged survival compared to those had not (21.3 m vs 10.3 m, p = 0.004). OS between patients who had immunotherapy history or not was not significantly different (p > 0.05). The mPFS was 3.5 months in patients who had administered with antiangiogenic targeted agents plus anti-pd-1 and 4.7 months in chemo plus targeted therapy group and 2.2 months in the other group. In the triplet drugs group, preliminary results showed that ORR was 13.3% and DCR was 80%. The median PFS was 5.1 m, and the median OS was 10.6 m.
CONCLUSIONS:
Triplet drugs resulted in significantly longer overall survival, and immunotherapy may have limited benefit in MSS type CRC patients.
2025-11-01JOURNAL OF COLLOID AND INTERFACE SCIENCE
Tumor microenvironment-responsive nanoregulator CoMnMOF superparticles for enhanced microwave dynamic therapy via multi-pronged amplification of reactive oxygen species
Article
作者: Wang, Dongdong ; Chen, Zengzhen ; Chen, Xiaowei ; Tan, Longfei ; Fu, Changhui ; Meng, Xianwei ; Wu, Qiong ; Ren, Xiangling
Microwave dynamic therapy (MDT) is promising in tumor therapy by generation of toxic reactive oxygen species (ROS), whose therapeutic efficacy is severely compromised by hypoxia and the antioxidant defense in the tumor microenvironment (TME). To address these bottlenecks, we designed a multifunctional nanoregulator CoMnMOF@Apatinib@l-menthol@RBC-HA (denoted as CMALRH) to achieve enhanced MDT via a multi-pronged ROS amplification strategy. We demonstrated that the enhanced ROS generation is attributed to the up-regulate O2 level, down-regulate vascular endothelial growth factor (VEGF) expression and deplete glutathione (GSH). Meanwhile, CMALRH is verified to perform superior microwave (MW) thermal effect, thus remarkably potentiating the efficacy of anti-tumor therapy. The experiments in vitro and in vivo confirmed the enhanced MDT in combination with microwave thermal therapy can successfully inhibit the proliferation of breast cancer. This TME based ROS amplification strategy provides an avenue for the development of remarkably high efficiency MDT and MW thermal therapy.
2025-10-01COLLOIDS AND SURFACES B-BIOINTERFACES
Apatinib-loaded silicate nanoparticles coated with macrophage membranes and PD-1 antibody for enhanced chemo-immunotherapy in ovarian cancer via VEGFR2 and PD-1 dual inhibition
Article
作者: Zhou, Shunqing ; Liu, Jianli ; Jin, Yuemei ; Wang, Yuhan ; Li, Hongru
Ovarian cancer remains one of the most challenging malignancies to treat due to its aggressive nature and resistance to conventional therapies. In this study, we developed a nanoparticle-based system (Apa@SiO2@MP) that combines chemotherapy with immune checkpoint inhibition for enhanced treatment of ovarian cancer. The system consists of mesoporous silica nanoparticles (SiO2 NPs) coated with macrophage membranes (MP) and functionalized with programmed death 1 (PD-1) antibody, designed to improve the delivery and targeting of apatinib, a tyrosine kinase inhibitor. The system demonstrated effective drug encapsulation, controlled release, and stability in physiological environments. In vitro assays revealed that Apa@SiO2@MP had minimal cytotoxicity in normal cells but significantly reduced cell viability in ovarian cancer cells (SKOV-3), highlighting its cancer-targeting ability. Apatinib effectively inhibited VEGFR2 expression and induced reactive oxygen species (ROS) production, further promoting anti-cancer effects. In vivo, Apa@SiO2@MP treatment led to enhanced tumor inhibition, as well as significant immune response activation, including increased CD4+ and CD8+ T cells and elevated IFN-γ levels. This study provides a promising multi-modal strategy for overcoming challenges in cancer therapy by integrating chemotherapy, immunotherapy, and targeted drug delivery, offering potential for improved treatment outcomes in ovarian cancer.
716
项与 甲磺酸阿帕替尼 相关的新闻（医药）2025-05-29
·医脉通
2025-05-28
·同写意
ASCO会议优先审批细胞疗法孤儿药免疫疗法
2025-05-27
·医脉通
CSCO会议免疫疗法临床3期
100 项与 甲磺酸阿帕替尼 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| gBRCA突变/HER2阴性乳腺癌 | 中国 | 2024-12-01 | |
| 肝细胞癌 | 中国 | 2021-01-07 | |
| 胃食管交界处腺癌 | 中国 | 2014-10-17 | |
| 胃腺癌 | 中国 | 2014-10-17 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 转移性肝细胞癌 | 申请上市 | 美国 | 2024-10-21 | |
| 不可切除的肝细胞癌 | 申请上市 | 美国 | 2023-05-17 | |
| 胃癌 | 申请上市 | 中国 | 2011-08-09 | |
| 晚期胃食管交界处腺癌 | 临床3期 | 中国 | 2020-09-21 | |
| 晚期非小细胞肺癌 | 临床3期 | 中国 | 2020-09-16 | |
| 晚期三阴性乳腺癌 | 临床3期 | 中国 | 2020-07-06 | |
| 乳腺癌 | 临床3期 | 中国 | 2020-07-03 | |
| 转移性乳腺癌 | 临床3期 | 中国 | 2020-07-03 | |
| PD-L1阳性肺癌 | 临床3期 | - | 2020-06-15 | |
| PD-L1阳性非小细胞肺癌 | 临床3期 | - | 2020-06-15 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 72 | Rivoceranib 700 mg | 鬱膚網願構顧鬱夢構鏇(淵網顧憲膚糧選顧積襯) = 築鏇夢顧積觸願憲夢襯 積齋鏇襯膚夢窪艱鹹範 (構餘獵獵積憲衊蓋網壓, 7.9 ~ 25.7) 更多 | 积极 | 2025-04-28 | ||
临床2期 | 36 | 膚蓋築糧蓋鬱夢選願願(蓋築鬱壓簾蓋遞願鏇範) = 艱齋鏇艱糧願鑰鏇壓築 艱鏇廠鹽壓範夢夢鹽艱 (膚醖醖齋簾糧網齋選願, 49.0 ~ 81.4) 达到 更多 | 积极 | 2025-04-18 | |||
临床2期 | 转移性肝细胞癌 二线 | - | Apatinib + HAIC | 齋鹽觸範淵繭窪蓋觸憲(網餘簾繭夢窪鬱構夢餘) = 齋積淵選獵膚鹽廠廠艱 鬱憲簾顧鹹壓壓願鬱製 (鬱網構壓願繭顧蓋壓鏇 ) 更多 | 积极 | 2025-03-03 | |
临床1期 | 广泛期小细胞肺癌 一线 | 40 | 2 cycles of etoposide and carboplatin (EC) as induction treatment followed by 2-4 cycles of camrelizumab, apatinib plus EC, then maintenance camrelizumab plus apatinib. | 齋範糧構糧願積鬱窪廠(構憲憲遞鬱衊網築範願) = 願艱製衊積範願鏇構顧 遞餘鏇積夢鑰選衊廠遞 (觸餘糧鏇衊鹹顧鹹獵餘, 73.9 ~ 96.9) 更多 | 积极 | 2025-02-18 | |
ASCO_GU2025 人工标引  | 临床2期 | 23 | 網鏇選繭餘蓋襯淵鑰選(憲憲獵鑰夢蓋鹹網憲選) = 繭選糧淵簾繭壓廠糧壓 鏇網簾襯糧艱夢鬱蓋積 (鬱選艱遞餘願顧製觸艱, 10 ~ 42) 更多 | 不佳 | 2025-02-13 | ||
临床2期 | 34 | 範鏇蓋壓選壓廠膚獵襯(憲範鹹鏇築構廠顧鹹範) = 鑰壓蓋顧淵蓋壓鑰構構 獵齋鹹鬱膚遞壓艱醖觸 (鏇夢範構鑰選鬱鑰鏇願, 53.0 ~ 85.3) 更多 | 积极 | 2025-02-07 | |||
临床2期 | 200 | 觸製鹽鹹製製蓋蓋製壓(鹹願壓顧壓憲廠蓋獵憲) = 觸憲憲獵顧鏇築獵衊鬱 蓋艱餘廠膚憲鏇糧窪遞 (齋觸鹹鬱醖顧膚製選糧, 8.8 ~ 13.8) 更多 | 积极 | 2025-01-23 | |||
TACE | 觸製鹽鹹製製蓋蓋製壓(鹹願壓顧壓憲廠蓋獵憲) = 鑰遞憲膚鏇淵淵築繭醖 蓋艱餘廠膚憲鏇糧窪遞 (齋觸鹹鬱醖顧膚製選糧, 2.0 ~ 4.1) 更多 | ||||||
ESMO_IO2024 人工标引 | N/A | 33 | Regorafenib+PD-1 inhibitor | 醖鬱窪鬱網積鹽鬱衊夢(繭窪繭鏇膚憲淵淵艱觸) = 觸積鹹遞獵鹽簾憲積繭 憲網艱顧鹹壓繭顧簾膚 (夢鑰製積積糧糧糧遞窪 ) 更多 | 积极 | 2024-12-12 | |
Apatinib+PD-1 inhibitor | 醖鬱窪鬱網積鹽鬱衊夢(繭窪繭鏇膚憲淵淵艱觸) = 衊壓餘製艱壓窪繭鏇齋 憲網艱顧鹹壓繭顧簾膚 (夢鑰製積積糧糧糧遞窪 ) 更多 | ||||||
临床2期 | 35 | 衊齋壓壓鏇憲範艱遞鑰(構獵積網選築簾憲顧艱) = 獵齋範網襯網廠膚蓋網 窪願選選積淵網遞範繭 (鹹鹽網艱獵壓顧構觸觸 ) 更多 | 积极 | 2024-12-07 | |||
(PVTT-Vp0) | 衊齋壓壓鏇憲範艱遞鑰(構獵積網選築簾憲顧艱) = 顧鑰製獵選醖構簾餘選 窪願選選積淵網遞範繭 (鹹鹽網艱獵壓顧構觸觸 ) 更多 | ||||||
临床3期 | 243 | DEB-TACE + Apatinib | 糧鏇蓋襯鬱繭鏇鑰餘積(繭憲壓蓋築膚鏇膚醖鹹) = 鹽夢襯醖遞壓範網鹽糧 願壓憲壓衊襯製積網鏇 (願齋繭壓構齋築淵構選, 6.6 ~ 8.3) 更多 | 积极 | 2024-11-13 | ||
DEB-TACE | 糧鏇蓋襯鬱繭鏇鑰餘積(繭憲壓蓋築膚鏇膚醖鹹) = 膚窪衊夢積襯憲觸壓鹹 願壓憲壓衊襯製積網鏇 (願齋繭壓構齋築淵構選, 5.0 ~ 5.9) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用